Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges

Neoadjuvant immunotherapy involves administering immune checkpoint inhibitors before surgical resection in high-risk resectable disease. This strategy was shown to have a high pathological response rate and prolonged relapse-free survival in randomized trials in melanoma, glioblastoma, and colon can...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnamoorthy, Mithunah, Lenehan, John G, Maleki Vareki, Saman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246900/
https://www.ncbi.nlm.nih.gov/pubmed/33432320
http://dx.doi.org/10.1093/jnci/djaa216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246900/
https://www.ncbi.nlm.nih.gov/pubmed/33432320
http://dx.doi.org/10.1093/jnci/djaa216

Ejemplares similares